NO20003422D0 - Arylfusjonerte azapolycykliske forbindelser - Google Patents

Arylfusjonerte azapolycykliske forbindelser

Info

Publication number: NO20003422D0
Authority: NO; Norway
Prior art keywords: aryl; fused azapolycyclic; azapolycyclic compounds; compounds; fused
Prior art date: 1997-12-31

Application number

NO20003422A

Other languages

English (en)

Other versions

NO319115B1 (no

NO20003422L (no

Inventor

Jotham Wadsworth Coe

Paige Roanne Palmer Brooks

Original Assignee

Pfizer Prod Inc

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1997-12-31

Filing date

2000-06-30

Publication date

2000-06-30

Family has litigation

First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=22094096&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=NO20003422(D0) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.

2000-06-30 Application filed by Pfizer Prod Inc filed Critical Pfizer Prod Inc

2000-06-30 Publication of NO20003422D0 publication Critical patent/NO20003422D0/no

2000-08-29 Publication of NO20003422L publication Critical patent/NO20003422L/no

2005-06-20 Publication of NO319115B1 publication Critical patent/NO319115B1/no

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D221/00—Heterocyclic compounds containing six-membered rings having one nitrogen atom as the only ring hetero atom, not provided for by groups C07D211/00 - C07D219/00
- C07D221/02—Heterocyclic compounds containing six-membered rings having one nitrogen atom as the only ring hetero atom, not provided for by groups C07D211/00 - C07D219/00 condensed with carbocyclic rings or ring systems
- C07D221/22—Bridged ring systems
- C07D221/24—Camphidines
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/473—Quinolines; Isoquinolines ortho- or peri-condensed with carbocyclic ring systems, e.g. acridines, phenanthridines
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/06—Antimigraine agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/08—Antiepileptics; Anticonvulsants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/20—Hypnotics; Sedatives
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
- A61P25/32—Alcohol-abuse
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
- A61P25/34—Tobacco-abuse
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
- A61P25/36—Opioid-abuse
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/06—Antiarrhythmics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D221/00—Heterocyclic compounds containing six-membered rings having one nitrogen atom as the only ring hetero atom, not provided for by groups C07D211/00 - C07D219/00
- C07D221/02—Heterocyclic compounds containing six-membered rings having one nitrogen atom as the only ring hetero atom, not provided for by groups C07D211/00 - C07D219/00 condensed with carbocyclic rings or ring systems
- C07D221/22—Bridged ring systems
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/08—Bridged systems
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D513/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
- C07D513/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains two hetero rings
- C07D513/08—Bridged systems

Landscapes

Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Organic Chemistry (AREA)
Animal Behavior & Ethology (AREA)
Veterinary Medicine (AREA)
Bioinformatics & Cheminformatics (AREA)
Engineering & Computer Science (AREA)
Pharmacology & Pharmacy (AREA)
Medicinal Chemistry (AREA)
General Health & Medical Sciences (AREA)
Public Health (AREA)
Life Sciences & Earth Sciences (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
General Chemical & Material Sciences (AREA)
Chemical Kinetics & Catalysis (AREA)
Biomedical Technology (AREA)
Neurosurgery (AREA)
Neurology (AREA)
Addiction (AREA)
Psychiatry (AREA)
Pain & Pain Management (AREA)
Heart & Thoracic Surgery (AREA)
Cardiology (AREA)
Diabetes (AREA)
Psychology (AREA)
Hematology (AREA)
Epidemiology (AREA)
Obesity (AREA)
Rheumatology (AREA)
Child & Adolescent Psychology (AREA)
Anesthesiology (AREA)
Hospice & Palliative Care (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Nitrogen Condensed Heterocyclic Rings (AREA)
Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
Other In-Based Heterocyclic Compounds (AREA)
Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
Plural Heterocyclic Compounds (AREA)
Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)

NO20003422A 1997-12-31 2000-06-30 Arylfusjonerte azapolycykliske forbindelser, anvendelse derav samt farmasoytiske sammensetninger. NO319115B1 (no)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
US7024597P	1997-12-31	1997-12-31
PCT/IB1998/001813 WO1999035131A1 (en)	1997-12-31	1998-11-13	Aryl fused azapolycyclic compounds

Publications (3)

Publication Number	Publication Date
NO20003422D0 true NO20003422D0 (no)	2000-06-30
NO20003422L NO20003422L (no)	2000-08-29
NO319115B1 NO319115B1 (no)	2005-06-20

Family

ID=22094096

Family Applications (2)

Application Number	Title	Priority Date	Filing Date
NO20003422A NO319115B1 (no)	1997-12-31	2000-06-30	Arylfusjonerte azapolycykliske forbindelser, anvendelse derav samt farmasoytiske sammensetninger.
NO2006016C NO2006016I1 (no)	1997-12-31	2006-11-17	7,8,9,10-tetrahydro-6H-6,10-metanoazepinoÄ4,5-gÜkinoksalintartrat

Family Applications After (1)

Application Number	Title	Priority Date	Filing Date
NO2006016C NO2006016I1 (no)	1997-12-31	2006-11-17	7,8,9,10-tetrahydro-6H-6,10-metanoazepinoÄ4,5-gÜkinoksalintartrat

Country Status (51)

Country	Link
US (6)	US6410550B1 (no)
EP (2)	EP1044189B2 (no)
JP (1)	JP3550359B2 (no)
KR (1)	KR100408138B1 (no)
CN (2)	CN1715280A (no)
AP (1)	AP1170A (no)
AR (1)	AR017967A1 (no)
AT (1)	ATE386024T1 (no)
AU (1)	AU753389C (no)
BG (1)	BG65058B1 (no)
BR (2)	BR9816186B1 (no)
CA (1)	CA2316921C (no)
CO (1)	CO4810373A1 (no)
CY (2)	CY1107391T1 (no)
CZ (1)	CZ301925B6 (no)
DE (2)	DE69839131T3 (no)
DK (1)	DK1044189T4 (no)
DZ (1)	DZ2697A1 (no)
EA (1)	EA003190B1 (no)
EG (1)	EG23816A (no)
ES (1)	ES2301210T5 (no)
FR (1)	FR08C0039I2 (no)
GT (2)	GT199800200A (no)
HN (1)	HN1998000177A (no)
HR (2)	HRP20000445B1 (no)
HU (2)	HU230297B1 (no)
IL (2)	IL136727A0 (no)
IS (1)	IS5514A (no)
LU (1)	LU91442I2 (no)
MA (1)	MA26589A1 (no)
ME (1)	ME00459B (no)
MY (1)	MY118163A (no)
NL (1)	NL300355I2 (no)
NO (2)	NO319115B1 (no)
NZ (1)	NZ504482A (no)
OA (1)	OA11428A (no)
PA (1)	PA8463901A1 (no)
PE (1)	PE20000053A1 (no)
PL (1)	PL209404B1 (no)
PT (1)	PT1044189E (no)
RS (1)	RS50069B (no)
SA (1)	SA99191123B1 (no)
SG (1)	SG102686A1 (no)
SI (1)	SI1044189T2 (no)
SK (1)	SK286886B6 (no)
TN (1)	TNSN98237A1 (no)
TR (1)	TR200001840T2 (no)
TW (1)	TW513412B (no)
UA (1)	UA66825C2 (no)
WO (1)	WO1999035131A1 (no)
ZA (1)	ZA9811911B (no)

Families Citing this family (93)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
TR200001840T2 (tr) *	1997-12-31	2000-12-21	Pfizer Products Inc.	Arile bağlı azopolisiklik bileşikler
US6605610B1 (en) *	1997-12-31	2003-08-12	Pfizer Inc	Aryl fused azapolycyclic compounds
CA2380072C (en)	1999-07-28	2007-07-10	John Cooke	Nicotine in therapeutic angiogenesis and vasculogenesis
US8188043B2 (en)	1999-07-28	2012-05-29	The Board Of Trustees Of The Leland Stanford Jr. University	Nicotine in therapeutic angiogenesis and vasculogenesis
IL137937A0 (en) *	1999-08-27	2001-10-31	Pfizer Prod Inc	A pharmaceutical composition for the prevention and treatment of nicotine addiction in a mammal
US20020010192A1 (en) *	2000-06-02	2002-01-24	Coe Jotham Wadsworth	Pharmaceutical composition for the treatment of obesity or to facilitate or promote weight loss
US20020016334A1 (en) *	2000-07-31	2002-02-07	Coe Jotham Wadsworth	Pharmaceutical composition for the treatment of attention deficit hyperactivity disorder (ADHD)
PT1383733E (pt) *	2001-04-20	2008-04-15	Pfizer Prod Inc	Processo para a preparação de indenos 1,3-substituídos e compostos azapolicíclicos fundidos com arilo
JP3779682B2 (ja) *	2001-05-14	2006-05-31	ファイザー・プロダクツ・インク	５，８，１４−トリアザテトラシクロ［１０．３．１．０２，１１．０４，９］−ヘキサデカ−２（１１），３，５，７，９−ペンタンの酒石酸塩及びその医薬組成物
MXPA03010365A (es) *	2001-05-14	2004-03-16	Pfizer Prod Inc	Sal citrato de 5,7,14-triazatetraciclo [10.3.1.02,11.04,9]-hexadeca-2(11),3,5,7,9-pentaeno y composiciones farmaceuticas de la misma.
ES2258652T3 (es)	2001-11-29	2006-09-01	Pfizer Products Inc.	Sales de succinato de 5,8,14-triazatetraciclo(10.3.1.02,11.04,9)-hexadeca-2(11),3,5,7,9-pentaeno y composiciones farmaceuticas de los mismos.
IL161836A0 (en)	2001-11-30	2005-11-20	Pfizer Prod Inc	Aryl fused azapolycyclic compounds
IL161857A0 (en) *	2001-11-30	2005-11-20	Pfizer Prod Inc	Pharmaceutical compositions of 5,7,14-triazatetracycloÄ10.3.1.0(2,11).0(4,9)Ü-hexadeca-2(11)3,5,7,9-pentaene
US8143210B2 (en) *	2002-02-14	2012-03-27	The Board Of Trustees Of The Leland Stanford Junior University	Enzyme treatment of foodstuffs for celiac sprue
US7320788B2 (en) *	2002-02-14	2008-01-22	The Board Of Trustees Of The Leland Stanford Junior University	Enzyme treatment of foodstuffs for Celiac Sprue
AU2003215272B2 (en)	2002-02-14	2008-04-03	The Board Of Trustees Of The Leland Stanford Junior University	Enzyme treatment of foodstuffs for celiac sprue
US7202216B2 (en) *	2002-05-14	2007-04-10	The Board Of Trustees Of The Leland Stanford Junior University	Drug therapy for celiac sprue
US7462688B2 (en) *	2002-05-14	2008-12-09	The Board Of Trustees Of The Leland Stanford Junior University	Peptides for diagnostic and therapeutic methods for celiac sprue
US7265093B2 (en) *	2002-05-14	2007-09-04	The Board Of Trustees Of The Leland Stanford Junior University	Drug therapy for Celiac Sprue
WO2003096979A2 (en) *	2002-05-14	2003-11-27	The Board Of Trustees Of The Leland Stanford Junior University	Drug therapy for celiac sprue
JP2006506432A (ja)	2002-11-20	2006-02-23	ファイザー・プロダクツ・インク	インダン−１，３−ジカルボン酸の製造方法
ATE554392T1 (de) *	2002-11-20	2012-05-15	Univ Leland Stanford Junior	Diagnoseverfahren für sprue/zöliakie
RU2284319C2 (ru) *	2002-11-25	2006-09-27	Пфайзер Продактс Инк.	Усовершенствованный способ получения 1,3-замещенных инденов
AU2004203983A1 (en) *	2003-01-15	2004-07-29	Pfizer Products Inc.	Process for the preparation of aryl fused polycyclic lactams
US20040224963A1 (en) *	2003-05-09	2004-11-11	Pfizer Inc	Pharmaceutical composition for the prevention and treatment of nicotine addiction in a mammal
US20040224962A1 (en) *	2003-05-09	2004-11-11	Pfizer Inc	Pharmaceutical composition for the treatment of obesity or to facilitate or promote weight loss
BRPI0410219A (pt) *	2003-05-20	2006-05-09	Pfizer Prod Inc	composições farmacêuticas de vareniclina
DK1638971T3 (da) *	2003-06-04	2008-10-27	Pfizer Prod Inc	Fremstilling af substitueret Quinoxaliner fra dianilinen med 2,3-dihydroxy-1,4-dioxan
JP2006528170A (ja) *	2003-07-21	2006-12-14	ファイザー・プロダクツ・インク	アリール縮合型アザ多環式化合物
JP2006528169A (ja) *	2003-07-21	2006-12-14	ファイザー・プロダクツ・インク	ニコチン嗜癖を低減するヘテロアリール縮合アザ多環式化合物
US20050043406A1 (en) *	2003-08-22	2005-02-24	Pfizer Inc	Pharmaceutical composition for the treatment of obesity or to facilitate or promote weight loss
US20050043407A1 (en) *	2003-08-22	2005-02-24	Pfizer Inc	Pharmaceutical composition for the prevention and treatment of addiction in a mammal
US7579313B2 (en)	2003-11-18	2009-08-25	The Board Of Trustees Of The Leland Stanford Junior University	Transglutaminase inhibitors and methods of use thereof
US7534426B2 (en) *	2004-04-26	2009-05-19	The Board Of Trustees Of The Leland Stanford Junior University	Glutenase enzyme assays
US7563864B2 (en) *	2004-04-26	2009-07-21	Celiac Sprue Research Foundation	Prolyl endopeptidase mediated destruction of T cell epitopes in whole gluten
US7628985B2 (en) *	2004-04-26	2009-12-08	The Board Of Regents Of The Leland Stanford Junior University	Therapeutic enzyme formulations and uses thereof in celiac sprue and/or dermatitis herpetoformis
WO2006006071A1 (en) *	2004-07-07	2006-01-19	Pfizer Products Inc.	Resolution of an aryl-fused azapolycyclic compound
US7766018B2 (en) *	2004-09-30	2010-08-03	Smoke-Break, Inc.	Device and composition for reducing the incidence of tobacco smoking
CA2598533A1 (en) *	2005-02-24	2006-08-31	Pfizer Products Inc.	Preparation of high purity substituted quinoxaline
US20060211649A1 (en) *	2005-03-21	2006-09-21	Eric Marchewitz	Use of cytisine for enhancing physical performance
EP1976495A2 (en) *	2006-01-06	2008-10-08	Aarhus Universitet	Compounds acting on the serotonin transporter
EP2004186A2 (en) *	2006-03-27	2008-12-24	Pfizer Products Inc.	Varenicline standards and impurity controls
RU2403016C2 (ru) *	2006-04-24	2010-11-10	Пфайзер Продактс Инк.	Асимметричные мембраны для устройств доставки лекарственного препарата
EP2083921A2 (en)	2006-09-04	2009-08-05	Neurosearch A/S	Pharmaceutical combinations of a nicotine receptor modulator and a cognitive enhancer
CA2666327A1 (en) *	2006-11-09	2008-05-22	Pfizer Products Inc.	Polymorphs of nicotinic intermediates
AU2008229448B2 (en) *	2007-03-16	2013-01-24	The Board Of Trustees Of The Leland Stanford Junior University	Combination enzyme therapy for digestion of dietary gluten
WO2009034431A2 (en)	2007-09-10	2009-03-19	Pfizer Inc.	Controlled-release dosage forms for varenicline
WO2009101185A2 (en) *	2008-02-15	2009-08-20	Medichem, S.A.	A NEW POLYMORPHIC FORM OF A PYRAZINO[2,3-h][3] BENZAZEPINE DERIVATIVE
US20090215787A1 (en) *	2008-02-22	2009-08-27	Mai De Ltd.	Preparations of new polymorphic forms of varenicline tartrate
JP2011516489A (ja)	2008-03-31	2011-05-26	ユニバーシティ・オブ・サウス・フロリダ	疾患誘発性運動失調症および非運動失調性平衡異常の治療法
WO2009143347A2 (en) *	2008-05-22	2009-11-26	Teva Pharmaceutical Industries Ltd.	Varenicline tosylate, an intermediate in the preparation process of varenicline l-tartrate
US20090318460A1 (en) *	2008-05-26	2009-12-24	Glenmark	Amorphous varenicline tartrate and process for the preparation thereof
WO2009155403A2 (en) *	2008-06-19	2009-12-23	Teva Pharmaceutical Industries Ltd.	Processes for the preparation of varenicline and intermediates thereof
US20100010221A1 (en) *	2008-07-10	2010-01-14	Revital Lifshitz-Liron	Processes for purifying varenicline l-tartrate salt and preparing crystalline forms of varenicline l-tartrate salt
EP2334679A1 (en) *	2008-09-01	2011-06-22	Actavis Group PTC EHF	Process for preparing varenicline, varenicline intermediates, and pharmaceutically acceptable salts thereof
EP2204369A1 (en)	2008-12-22	2010-07-07	Medichem, S.A.	Process for preparing varenicline and intermediates for use therein
SG173639A1 (en) *	2009-02-11	2011-09-29	Sunovion Pharmaceuticals Inc	Histamine h3 inverse agonists and antagonists and methods of use thereof
US20120093887A1 (en)	2009-06-10	2012-04-19	Actavis Group Ptc Ehf	Amorphous varenicline tartrate co-precipitates
RU2012102052A (ru)	2009-06-22	2013-11-20	Тева Фармасьютикал Индастриз Лтд.	Твердые формы солей варениклина и способы их получения
CA2772525A1 (en) *	2009-09-11	2011-03-17	Sunovion Pharmaceuticals Inc.	Histamine h3 inverse agonists and antagonists and methods of use thereof
US20130101630A1 (en)	2010-03-09	2013-04-25	Actavis Group Ptc Ehf	Highly pure varenicline or a pharmaceutically acceptable salt thereof substantially free of methylvarenicline impurity
KR101109389B1 (ko) *	2010-04-30	2012-01-30	삼성전기주식회사	인쇄회로기판 및 그 제조방법
WO2011140431A1 (en)	2010-05-06	2011-11-10	Teva Pharmaceutical Industries Ltd.	Varenicline salts and crystal forms thereof
US20120004239A1 (en)	2010-06-11	2012-01-05	Medichem, S.A.	Process for Preparing Quinoxaline Derivatives
AU2012276651A1 (en)	2011-06-30	2014-02-06	Toray Industries, Inc.	Antipruritic agent
ITMI20111413A1 (it)	2011-07-28	2013-01-29	Dipharma Francis Srl	Procedimento per la preparazione di vareniclina
ES2426517B1 (es)	2012-04-20	2014-05-14	Genetracer Biotech S.L	Método para predecir la seguridad de un tratamiento farmacológico
ES2426838B1 (es)	2012-04-20	2014-05-07	Genetracer Biotech S.L	Método para predecir el éxito en el abandono del consumo de tabaco en respuesta a un tratamiento farmacológico
CN103570502A (zh) *	2012-07-18	2014-02-12	上海科胜药物研发有限公司	一种伐伦克林中间体的制备方法
US9636340B2 (en)	2013-11-12	2017-05-02	Ayyappan K. Rajasekaran	Kinase inhibitors
CN103992272B (zh) *	2014-06-09	2016-05-11	安徽省逸欣铭医药科技有限公司	一种盐酸喷他佐辛酯、其制备方法及其用途
KR20160126697A (ko)	2015-04-24	2016-11-02	한미정밀화학주식회사	신규 결정형의 바레니클린 옥살산 염 수화물, 이의 제조방법, 및 이를 포함하는 약학 조성물
KR20160143407A (ko)	2015-06-05	2016-12-14	한미정밀화학주식회사	신규한 바레니클린 뮤케이트 염, 이의 결정형 및 이의 제조방법
KR101724301B1 (ko)	2016-11-22	2017-04-10	주식회사 한서켐	바레니클린 살리실산염의 i형 결정 및 그 제조방법
CN106674194B (zh) *	2016-12-14	2019-03-05	山东省联合农药工业有限公司	一种结构新颖的烟碱类杀虫剂及其制备方法和用途
WO2018160043A1 (ko)	2017-03-03	2018-09-07	주식회사 씨티씨바이오	바레니클린 또는 이의 약학적으로 허용가능한 염의 포접 복합체를 포함하는 구강 투여용 제제
KR102463733B1 (ko)	2017-06-30	2022-11-04	한미약품 주식회사	함량 균일성 및 안정성이 향상된 바레니클린 옥살산염이 포함된 약제학적 조성물
WO2018154395A2 (en)	2018-06-11	2018-08-30	Alvogen Malta Operations (Row) Ltd	Controlled release pharmaceutical composition of varenicline
KR20200034293A (ko)	2018-09-21	2020-03-31	한미약품 주식회사	제어 방출용 바레니클린 제제
EP4142734B1 (en)	2020-04-28	2025-08-20	Oyster Point Pharma, Inc.	Local administration of nicotinic acetylcholine receptor agonists for the inhibition of coronavirus infections
CN113956255A (zh) *	2020-07-20	2022-01-21	威智医药有限公司	一种伐尼克兰中间体、伐尼克兰及其盐的制备方法
US11040983B1 (en)	2020-08-14	2021-06-22	Almatica Pharma Llc	Cocrystal of varenicline and oxalic acid, pharmaceutical composition thereof, and methods of use thereof
WO2022035434A1 (en)	2020-08-14	2022-02-17	Almatica Pharma Llc	Cocrystal of varenicline and oxalic acid, pharmaceutical composition thereof, and methods of use thereof
WO2022147189A1 (en) *	2020-12-30	2022-07-07	Antares Pharma, Inc.	Varenicline prodrugs
WO2022222019A1 (en) *	2021-04-20	2022-10-27	Suzhou Fude Zhaofeng Biochemical Technology Co., Ltd	Total synthesis of varenicline
CN113277993B (zh) *	2021-06-06	2023-07-21	湖南第一师范学院	一种Tafamidis及其衍生物的合成方法
WO2023275413A2 (en)	2021-12-23	2023-01-05	Medichem, S.A.	Solid pharmaceutical formulations of varenicline
US11602537B2 (en)	2022-03-11	2023-03-14	Par Pharmaceutical, Inc.	Varenicline compound and process of manufacture thereof
EP4241775A1 (en)	2022-03-11	2023-09-13	Par Pharmaceutical, Inc.	Tablet comprising varenicline and process of preparation thereof
JP2025520426A (ja)	2022-06-14	2025-07-03	アミグダラニューロサイエンシーズ，インコーポレイテッド	Ａｌｄｈ－２阻害化合物及び使用方法
EP4611896A1 (en)	2022-11-04	2025-09-10	Pfizer Inc.	Prodrugs of varenicline and compounds containing vulnerable amines
IT202300003888A1 (it)	2023-03-03	2024-09-03	Dipharma Francis Srl	Processo di preparazione di un farmaco usato per trattare la dipendenza da nicotina
WO2024224270A1 (en)	2023-04-24	2024-10-31	Pfizer Inc.	Varenicline formulations

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US3471503A (en) *	1967-05-05	1969-10-07	Mcneilab Inc	1,2,3,5,6,7-hexahydro-4-phenethyl-2,6-methano-4h-4- benzazonin-12-ols
CH644116A5 (de) *	1980-08-21	1984-07-13	Hoffmann La Roche	Imidazolderivate.
EP0853621A1 (en) †	1995-09-22	1998-07-22	Novo Nordisk A/S	Novel substituted azacyclic or azabicyclic compounds
TR200001840T2 (tr) *	1997-12-31	2000-12-21	Pfizer Products Inc.	Arile bağlı azopolisiklik bileşikler
US6605610B1 (en) *	1997-12-31	2003-08-12	Pfizer Inc	Aryl fused azapolycyclic compounds
WO1999042461A1 (en) *	1998-02-23	1999-08-26	Warner-Lambert Company	Substituted quinoxaline derivatives as interleukin-8 receptor antagonists
EP0955301A3 (en) *	1998-04-27	2001-04-18	Pfizer Products Inc.	7-aza-bicyclo[2.2.1]-heptane derivatives, their preparation and use according to their affinity for neuronal nicotinic acetylcholine receptors
NZ507035A (en) *	1998-04-29	2003-05-30	Pfizer Prod Inc	Aryl fused azapolycyclic compounds
CN1345320A (zh) *	1999-01-29	2002-04-17	艾博特公司	用作烟碱性乙酰胆碱受体配体的二氮杂二环衍生物
FR2788982B1 (fr) *	1999-02-02	2002-08-02	Synthelabo	Compositions pharmaceutiques contenant de la nicotine et leur application dans le sevrage tabagique
IL137937A0 (en) *	1999-08-27	2001-10-31	Pfizer Prod Inc	A pharmaceutical composition for the prevention and treatment of nicotine addiction in a mammal
JP3779682B2 (ja) *	2001-05-14	2006-05-31	ファイザー・プロダクツ・インク	５，８，１４−トリアザテトラシクロ［１０．３．１．０２，１１．０４，９］−ヘキサデカ−２（１１），３，５，７，９−ペンタンの酒石酸塩及びその医薬組成物
MXPA03010365A (es) *	2001-05-14	2004-03-16	Pfizer Prod Inc	Sal citrato de 5,7,14-triazatetraciclo [10.3.1.02,11.04,9]-hexadeca-2(11),3,5,7,9-pentaeno y composiciones farmaceuticas de la misma.
ES2258652T3 (es) *	2001-11-29	2006-09-01	Pfizer Products Inc.	Sales de succinato de 5,8,14-triazatetraciclo(10.3.1.02,11.04,9)-hexadeca-2(11),3,5,7,9-pentaeno y composiciones farmaceuticas de los mismos.
IL161857A0 (en) *	2001-11-30	2005-11-20	Pfizer Prod Inc	Pharmaceutical compositions of 5,7,14-triazatetracycloÄ10.3.1.0(2,11).0(4,9)Ü-hexadeca-2(11)3,5,7,9-pentaene
IL161836A0 (en) *	2001-11-30	2005-11-20	Pfizer Prod Inc	Aryl fused azapolycyclic compounds
JP2006528170A (ja) *	2003-07-21	2006-12-14	ファイザー・プロダクツ・インク	アリール縮合型アザ多環式化合物

1998
- 1998-11-13 TR TR2000/01840T patent/TR200001840T2/xx unknown
- 1998-11-13 BR BRPI9816186-5A patent/BR9816186B1/pt not_active IP Right Cessation
- 1998-11-13 HR HR20000445A patent/HRP20000445B1/xx not_active IP Right Cessation
- 1998-11-13 ME MEP-2008-702A patent/ME00459B/me unknown
- 1998-11-13 ES ES98950274.5T patent/ES2301210T5/es not_active Expired - Lifetime
- 1998-11-13 RS YUP-403/00A patent/RS50069B/sr unknown
- 1998-11-13 HU HU0100949A patent/HU230297B1/hu active Protection Beyond IP Right Term
- 1998-11-13 EP EP98950274.5A patent/EP1044189B2/en not_active Expired - Lifetime
- 1998-11-13 IL IL13672798A patent/IL136727A0/xx active Protection Beyond IP Right Term
- 1998-11-13 DK DK98950274T patent/DK1044189T4/en active
- 1998-11-13 HR HR20050506A patent/HRP20050506A2/hr not_active Application Discontinuation
- 1998-11-13 JP JP2000527532A patent/JP3550359B2/ja not_active Expired - Lifetime
- 1998-11-13 EA EA200000592A patent/EA003190B1/ru not_active IP Right Cessation
- 1998-11-13 WO PCT/IB1998/001813 patent/WO1999035131A1/en not_active Ceased
- 1998-11-13 AU AU96416/98A patent/AU753389C/en not_active Expired
- 1998-11-13 US US09/402,010 patent/US6410550B1/en not_active Expired - Lifetime
- 1998-11-13 CN CNA2005100821428A patent/CN1715280A/zh active Pending
- 1998-11-13 UA UA2000063807A patent/UA66825C2/uk unknown
- 1998-11-13 CA CA002316921A patent/CA2316921C/en not_active Expired - Lifetime
- 1998-11-13 SI SI9830902T patent/SI1044189T2/sl unknown
- 1998-11-13 BR BRPI9814592-4A patent/BR9814592B1/pt not_active IP Right Cessation
- 1998-11-13 CZ CZ20002438A patent/CZ301925B6/cs not_active IP Right Cessation
- 1998-11-13 AT AT98950274T patent/ATE386024T1/de active
- 1998-11-13 CN CNB988128195A patent/CN1324013C/zh not_active Expired - Lifetime
- 1998-11-13 PT PT98950274T patent/PT1044189E/pt unknown
- 1998-11-13 NZ NZ504482A patent/NZ504482A/xx not_active IP Right Cessation
- 1998-11-13 PL PL341824A patent/PL209404B1/pl unknown
- 1998-11-13 SG SG200203917A patent/SG102686A1/en unknown
- 1998-11-13 DE DE69839131.4T patent/DE69839131T3/de not_active Expired - Lifetime
- 1998-11-13 KR KR10-2000-7007379A patent/KR100408138B1/ko not_active Expired - Lifetime
- 1998-11-13 EP EP05106853A patent/EP1659114A3/en not_active Withdrawn
- 1998-11-13 SK SK971-2000A patent/SK286886B6/sk not_active IP Right Cessation
- 1998-11-13 DE DE122008000038C patent/DE122008000038I1/de active Pending
- 1998-11-19 HN HN1998000177A patent/HN1998000177A/es unknown
- 1998-11-30 PA PA19988463901A patent/PA8463901A1/es unknown
- 1998-11-30 CO CO98070723A patent/CO4810373A1/es unknown
- 1998-12-15 GT GT199800200A patent/GT199800200A/es unknown
- 1998-12-15 GT GT199800200AK patent/GT199800200AA/es unknown
- 1998-12-17 AP APAP/P/1998/001422A patent/AP1170A/en active
- 1998-12-28 EG EG161298A patent/EG23816A/xx active
- 1998-12-28 TW TW087121748A patent/TW513412B/zh not_active IP Right Cessation
- 1998-12-28 PE PE1998001286A patent/PE20000053A1/es not_active IP Right Cessation
- 1998-12-29 ZA ZA9811911A patent/ZA9811911B/xx unknown
- 1998-12-29 AR ARP980106715A patent/AR017967A1/es active IP Right Grant
- 1998-12-30 MA MA25409A patent/MA26589A1/fr unknown
- 1998-12-30 TN TNTNSN98237A patent/TNSN98237A1/fr unknown
- 1998-12-30 DZ DZ980307A patent/DZ2697A1/xx active
- 1998-12-30 MY MYPI98005949A patent/MY118163A/en unknown
1999
- 1999-02-28 SA SA99191123A patent/SA99191123B1/ar unknown
2000
- 2000-05-26 IS IS5514A patent/IS5514A/is unknown
- 2000-06-12 IL IL136727A patent/IL136727A/en active Protection Beyond IP Right Term
- 2000-06-16 OA OA1200000175A patent/OA11428A/en unknown
- 2000-06-27 BG BG104561A patent/BG65058B1/bg unknown
- 2000-06-30 NO NO20003422A patent/NO319115B1/no not_active IP Right Cessation
2002
- 2002-02-13 US US10/075,843 patent/US6887884B2/en not_active Expired - Fee Related
- 2002-02-14 US US10/075,348 patent/US20020072524A1/en not_active Abandoned
- 2002-04-22 US US10/127,267 patent/US6951938B2/en not_active Expired - Lifetime
- 2002-04-23 US US10/131,278 patent/US6897310B2/en not_active Expired - Lifetime
2006
- 2006-11-17 NO NO2006016C patent/NO2006016I1/no not_active IP Right Cessation
2007
- 2007-07-17 US US11/778,890 patent/US20070275973A1/en not_active Abandoned
2008
- 2008-04-14 CY CY20081100397T patent/CY1107391T1/el unknown
- 2008-05-21 LU LU91442C patent/LU91442I2/fr unknown
- 2008-06-05 NL NL300355C patent/NL300355I2/nl unknown
- 2008-07-03 CY CY200800013C patent/CY2008013I2/el unknown
- 2008-07-21 FR FR08C0039C patent/FR08C0039I2/fr active Active
2016
- 2016-04-27 HU HUS1600018C patent/HUS1600018I1/hu unknown

Also Published As

Publication number	Publication date
AP9801422A0 (en)	1998-12-31
JP2002500218A (ja)	2002-01-08
DE69839131T2 (de)	2009-02-05
CA2316921A1 (en)	1999-07-15
DE122008000038I1 (de)	2008-11-13
US6887884B2 (en)	2005-05-03
NZ504482A (en)	2003-01-31
SI1044189T2 (sl)	2015-05-29
US6410550B1 (en)	2002-06-25
DK1044189T4 (en)	2015-03-30
CY2008013I1 (el)	2009-11-04
CA2316921C (en)	2004-12-07
MA26589A1 (fr)	2004-12-20
PL341824A1 (en)	2001-05-07
HU230297B1 (hu)	2015-12-28
US20020072524A1 (en)	2002-06-13
OA11428A (en)	2004-05-03
SK286886B6 (sk)	2009-07-06
NO2006016I1 (no)	2006-11-27
AP1170A (en)	2003-06-30
ES2301210T3 (es)	2008-06-16
ES2301210T5 (es)	2015-05-07
DK1044189T3 (da)	2008-05-13
SA99191123B1 (ar)	2006-10-02
EA003190B1 (ru)	2003-02-27
SG102686A1 (en)	2004-03-26
HRP20000445A2 (en)	2001-04-30
HUP0100949A2 (hu)	2001-08-28
CY2008013I2 (el)	2009-11-04
ZA9811911B (en)	2000-06-29
US20020132824A1 (en)	2002-09-19
GT199800200A (es)	2000-06-07
SI1044189T1 (sl)	2008-06-30
DZ2697A1 (fr)	2003-03-29
EA200000592A1 (ru)	2000-12-25
EP1044189B1 (en)	2008-02-13
EP1659114A3 (en)	2007-01-17
US6897310B2 (en)	2005-05-24
CZ20002438A3 (cs)	2002-11-13
DE69839131D1 (de)	2008-03-27
SK9712000A3 (en)	2002-03-05
UA66825C2 (uk)	2004-06-15
HRP20000445B1 (hr)	2009-04-30
NO2006016I2 (no)	2008-10-20
CN1324013C (zh)	2007-07-04
BR9814592B1 (pt)	2010-06-01
JP3550359B2 (ja)	2004-08-04
DE69839131T3 (de)	2015-05-07
CN1715280A (zh)	2006-01-04
PE20000053A1 (es)	2000-02-07
PL209404B1 (pl)	2011-08-31
MY118163A (en)	2004-09-30
HUS1600018I1 (hu)	2018-05-02
ATE386024T1 (de)	2008-03-15
EP1044189B2 (en)	2015-02-25
LU91442I9 (no)	2018-12-31
AU753389C (en)	2007-08-09
BG65058B1 (bg)	2007-01-31
PA8463901A1 (es)	2000-09-29
HN1998000177A (es)	1999-02-09
RS50069B (sr)	2009-01-22
FR08C0039I1 (no)	2008-11-14
AR017967A1 (es)	2001-10-24
IL136727A (en)	2006-06-11
AU9641698A (en)	1999-07-26
LU91442I2 (fr)	2008-07-21
US20020072525A1 (en)	2002-06-13
HUP0100949A3 (en)	2002-12-28
EP1659114A2 (en)	2006-05-24
CZ301925B6 (cs)	2010-08-04
NO319115B1 (no)	2005-06-20
TNSN98237A1 (fr)	2005-03-15
AU753389B2 (en)	2002-10-17
TR200001840T2 (tr)	2000-12-21
FR08C0039I2 (fr)	2009-12-18
GT199800200AA (es)	2000-06-07
IS5514A (is)	2000-05-26
US20070275973A1 (en)	2007-11-29
ME00459B (me)	2011-10-10
BG104561A (en)	2001-01-31
KR20010033823A (ko)	2001-04-25
EP1044189A1 (en)	2000-10-18
BR9816186B1 (pt)	2009-01-13
KR100408138B1 (ko)	2003-12-01
CO4810373A1 (es)	1999-06-30
WO1999035131A1 (en)	1999-07-15
BR9814592A (pt)	2000-10-17
YU40300A (sh)	2003-10-31
US20020111350A1 (en)	2002-08-15
IL136727A0 (en)	2001-06-14
HRP20050506A2 (en)	2006-03-31
EG23816A (en)	2007-09-19
CN1285821A (zh)	2001-02-28
NL300355I2 (nl)	2008-11-03
NL300355I1 (nl)	2008-08-01
HK1031878A1 (en)	2001-06-29
NO20003422L (no)	2000-08-29
PT1044189E (pt)	2008-04-22
CY1107391T1 (el)	2010-07-28
TW513412B (en)	2002-12-11
US6951938B2 (en)	2005-10-04

Publication	Publication Date	Title
NO20003422L (no)	2000-08-29	Arylfusjonerte azapolycykliske forbindelser
PT860428E (pt)	2005-04-29	Compostos pirimidiona
IS5479A (is)	2000-05-03	Efnasambönd
IS5478A (is)	2000-05-03	Efnasambönd
IS5477A (is)	2000-05-03	Efnasambönd
ID22850A (id)	1999-12-09	Senyawa-senyawa pirazina
NO994877D0 (no)	1999-10-07	Kalsilytiske forbindelser
IS5354A (is)	2000-01-20	Ný efnasambönd
EE200000321A (et)	2001-08-15	Uudsed ühendid
DE59810818D1 (de)	2004-04-01	Fügeverbindung
ID20323A (id)	1998-11-26	Senyawa-senyawa triazinilaminostilbena
ID24571A (id)	2000-07-27	Senyawa tienopirimidin
IS5208A (is)	1999-10-05	Efnasambönd
ID20635A (id)	1999-02-04	Senyawa metalosen
EE9900475A (et)	2000-06-15	Ühendid
NO996544D0 (no)	1999-12-29	Forbindelser
ID22983A (id)	1999-12-23	Senyawa-senyawa fluorometoksimino
NO995007D0 (no)	1999-10-14	Forbindelser
DE69737634D1 (de)	2007-05-31	Insektizide oxadiazinverbindungen
SE9702775D0 (sv)	1997-07-22	Novel compounds
ID18388A (id)	1998-04-02	Senyawa-senyawa heterosiklik
SE9701964D0 (sv)	1997-05-26	Compounds
ID21202A (id)	1999-05-06	Senyawa heterosiklik
SE9701397D0 (sv)	1997-04-15	Compounds
SE9702652D0 (sv)	1997-07-09	Novel compounds

Legal Events

Date	Code	Title	Description
2006-11-27	SPCF	Filing of supplementary protection certificate	Free format text: PRODUCT NAME: VARENIKLIN, EVENTUELT I FORM AV ET FARMASOEYTISK AKSEPTABELT SALT; NAT. REG. NO/DATE: EU106360001NO-010/NO 20061020; FIRST REG. NO/DATE: BE , EU106360001 20060928 Spc suppl protection certif: 2006016 Filing date: 20061117
2008-10-20	SPCG	Granted supplementary protection certificate	Free format text: PRODUCT NAME: VARENIKLIN, EVENTUELT I FORM AV ET FARMASOEYTISK AKSEPTABELT SALT; NAT. REG. NO/DATE: EU106360001NO-010/NO 20061020; FIRST REG. NO/DATE: BE , EU106360001 20060928 Spc suppl protection certif: 2006016 Filing date: 20061117 Extension date: 20210928
2016-03-07	SPCK	Change in the validity period of an spc	Free format text: PROTECTION PERIOD CHANGED TO: 20210928 Spc suppl protection certif: 2006016
2018-12-10	MK1K	Patent expired
2021-10-11	SPCX	Expiry of an spc	Free format text: PRODUCT NAME: VARENIKLIN, EVENTUELT I FORM AV ET FARMASOEYTISK AKSEPTABELT SALT; NAT. REG. NO/DATE: EU106360001NO-010/NO 20061020; FIRST REG. NO/DATE: BE , EU106360001 20060928 Spc suppl protection certif: 2006016